Liver abnormalities in pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) is a cardiopulmonary disease with high mortality. In recent years, it has been recognized that PAH is a multi-organ system disease, involving the systemic circulation, kidneys, skeletal muscles, and the central nervous system, among others. Right heart failure p...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Nils P. Nickel, Gian M. Galura, Marc J. Zuckerman, M. Nawar Hakim, Haider Alkhateeb, Debabrata Mukherjee, Eric D. Austin, Gustavo A. Heresi
Formato: article
Lenguaje:EN
Publicado: SAGE Publishing 2021
Materias:
Acceso en línea:https://doaj.org/article/8ff5dbda5de746daa6ac14ecc0538b4f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Pulmonary arterial hypertension (PAH) is a cardiopulmonary disease with high mortality. In recent years, it has been recognized that PAH is a multi-organ system disease, involving the systemic circulation, kidneys, skeletal muscles, and the central nervous system, among others. Right heart failure produces congestive hepatopathy, a disease state that has direct consequences on liver biochemistry, histology, and systemic glucose and lipid metabolism. This article aims to summarize the consequences of congestive hepatopathy with an emphasis on liver biochemistry, histology, and PAH-targeted therapy. Furthermore, PAH-specific changes in glucose and lipid metabolism will be discussed.